Latest Strategic Growth News

Control Bionics has achieved FDA registration for its NeuroStrip surface EMG platform, cementing its medical device status in the US and bolstering its appeal in clinical and research markets.

Ashley Services Group has finalised its acquisition announced in June, expanding its weekly workforce to over 10,000 during peak seasons and reinforcing its position in the labour hire sector.

Patronus Resources (ASX:PTN) is executing a major 30,000-metre multi-rig drilling campaign at its Pine Creek gold project, underpinning a 2.3 million ounce gold equivalent resource across its Northern Territory and Western Australia assets, supported by a robust $65 million cash position.

Scalare Partners has completed its acquisition of Fishburners, significantly boosting its founder network to around 40,000 and strengthening its national footprint. The company reported steady customer receipts of $5.29 million and raised a $5 million convertible note facility to fund ongoing growth.

Gratifii closed FY26 with record cash receipts of $66.3 million, completed a $10 million capital raise, acquired Mosh Social Media, and launched its new Connect+ platform powered by Marketplacer.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

Volt Group has delivered a record $5.1 million in half year revenue receipts for HY26, more than doubling prior year results, driven by strong contributions from its 4D Delta acquisition and solid performances across Wescone and EcoQuip.

Streamplay Studio Limited has reported its fifth straight quarter of positive operating cash flow, driven by strong customer receipts and strategic publishing deals. The company is advancing multiple game releases and expanding its cloud gaming footprint across new regions.

Stakk Ltd (ASX: SKK) has reported unaudited FY2026 revenue of A$14.68 million, beating prior guidance and delivering a 1,298% surge in customer cash receipts. The company also posted positive operating cash flow for the June quarter and anticipates further growth through its pending ParaScript acquisition.

ALS Limited reported record FY26 financial results driven by strong growth in Minerals and Industrial Materials, while advancing its digital transformation through the Lab of the Future initiative. Leadership changes and a strategic portfolio review underpin its disciplined capital allocation approach.

Resonance Health (ASX:RHT) closed FY26 with a net operating cash inflow of $2.9 million and completed recruitment for a $13.8 million clinical trial, underpinning a robust contract pipeline and growing net cash position.

MaxiPARTS upgrades FY26 operating profit guidance to $14.2 million, driven by strong cost control and a $9 million inventory reduction, while bolstering its executive team with key appointments.